We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

MaxCyte

Another year of strong delivery as CARMA approaches the clinic

Lighthouse | 04 April 2018

e-Therapeutics

A lean and mean drug discovery machine

Lighthouse | 27 March 2018

BerGenBio

Recruitment to first stage of TNBC Phase II completed ahead of schedule

Lighthouse | 19 February 2018

BerGenBio

Funded to achieve multiple value inflection points

Update | 15 February 2018

BerGenBio

Promising first clinical data in immuno-oncology

Update | 31 January 2018

BerGenBio

Initial clinical I-O data for bemcentinib (BGB324) is promising

Lighthouse | 29 January 2018

MaxCyte

First CARMA therapy to enter clinic in 2018

Update | 22 January 2018

e-therapeutics

Strengthening the platform through collaboration

Lighthouse | 15 January 2018

e-therapeutics

Good progress as first commercial deal sought

Update | 04 January 2018

BerGenBio

A rosy outlook for Axl

Initiation | 04 January 2018
1 2 3 4 5 6 7 8 9 10 11
110 results found.